PDCD1 and neoplasm: When tumor volumes reached 80–150 mm3 (Yumm2.1) and 150–200 mm3 (MC38), we initiated ICB treatment with anti-PD-1, which revealed that chronic UVR exposure reduced anti-PD-1 response in both Yumm2.1 and MC38 tumors (non-UVR anti-PD-1, UVR anti-PD-1, figure 2B,C, online supplemental figure 3F–I).